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1. Introduction 
The recent discovery that a series of lipotropin 
fragments possess opiate activity [l-3] has led to 
extensive investigation of the central properties of 
these peptides and discussion of their possible physio- 
logical roles. It has been suggested that each of the 
peptides is elaborated to perform a distinct function, 
methionine enkephalin (lipotropin 61--65) as a 
neurotransmitter [4], y-endorphin and cu-endorphin 
(61-77 and 61-76) in the maintenance of 
behavioural states [5] and C-Fragment (61-91) in 
pain perception [6]. However, the unique potency 
exhibited by C-Fragment in its central activities [7] 
would seem to imply that this is the physiologically 
significant peptide. 
A recent immunofluorescent study provided 
evidence that the enkephalins occur in the synaptic 
regions of nerve tracts in brain [8] but cross reactiv- 
ity of the antisera with the longer peptides was not 
examined and the evidence could indicate that 
C-Fragment or y-endorphin is present at the nerve 
junctions. Furthermore it has been shown that the 
enkephalins and endorphins can be formed by extra- 
cellular proteolysis of C-Fragment [9] and it is 
possible that the occurrence of the shorter peptides 
may reflect the occurrence of C-Fragment. 
This communication describes the preparation and 
study of an antiserum which has a high specificity 
for human lipotropin and for C-Fragment. It does 
not react significantly with y-endorphin or methionine 
enkephalin. The availability of this antiserum will 
open the way to study of the distribution of 
C-Fragment in specific regions of brain. 
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2. Materials and methods 
2.1. Preparation of antigen and peptides used in 
specificity study 
Human lipotropin was isolated from pooled 
pituitary glands [lo] . Porcine lipotropin (l-91), 
y-lipotropin (l-58), C-Fragment (61-91) and 
C’-Fragment (61-87) were isolated from porcine 
pituitary as described previously [2]. Human 
C-Fragment was prepared by Dr R. C. Sheppard and 
Dr E. Atherton by a modified solid phase synthesis 
[ 111; its in vitro binding properties to brain opiate 
receptors and its analgesic properties in the rat were 
similar to those of natural porcine C-Fragment. 
Methionine enkephalin and the hexapeptide 86-91 
were prepared by solid phase synthesis [12] and 
purified by ion-exchange chromatography on CM- 
Sephadex C25 and DEAE-Sephadex A-25 and by 
gel filtration on Sephadex G-l 5 in 50% (v/v) acetic 
acid. y-Endorphin and a tetradecapeptide (lipotropin 
78-91) were obtained by rennin digestion of porcine 
C-Fragment [13] ; the peptides were purified by gel 
filtration on Sephadex G-50 in 50% acetic acid and 
by high voltage electrophoresis on paper, at pH 1.9. 
[‘251]C-Fragment (approx. 400 &i/pg) was prepared 
by chloramine-T oxidation using a procedure similar 
to that reported for the labelling of ACTH [ 141; the 
peptide was purified on a column of Sephadex G-10. 
2.2. Immunization 
Antisera to human lipotropin were raised by 
irregular multisite injections in random-bred 
New-Zealand white rabbits using an emulsion of 
purified lipotropin in 10 mM sodium phosphate with 
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complete Freund’s adjuvant (1: 1). Injections were 
given over a period of 3 months, a total of 120 1.18 of 
human lipotropin being administered to each animal. 
Blood was collected at intervals after the last injection. 
2.3. Brain extracts 
Rats were stunned and decapitated; the brains 
were rapidly removed. After excision of pituitary, 
cerebellum and brain stem, the brain tissue was homo- 
genized at 4°C in 10 ml acid acetone (acetone/H*O/ 
HCl, 5:40: 1). The homogenate was centrifuged at 
20 000 X g for 10 min and the supernatant evaporated 
in vacua. The residue was examined by radioimmuno- 
assay. 
2.4. Radioimmunoassay procedure 
Incubations were performed in 0.05 M sodium 
phosphate (final vol. 300 ~1) at pH 7.6, containing 
0.25% human serum albumin (A. B. Kabi, Stockholm, 
Sweden), 0.5% mercaptoethanol and [‘251]C-Fragment 
(20 000 cpm, approx. 20 pg). Antibody was used at 
a dilution of 1: 1000, giving 50-60% saturation of 
binding. The concentrations of the peptide solutions 
were determined by amino acid analysis. Serial 
dilutions of each peptide were performed and 
incubations carried out for 24 h at 4°C in the presence 
of labelled C-Fragment and antiserum. Unbound. 
peptide was adsorbed on charcoal by addition of 
200 ~1 of a suspension of activated charcoal (3 g 
Sigma Chemical Co., St Louis, MO.) and dextran, 
mol. wt 73 000 (0.75 g, Sigma Chemical Co., 
St Louis, MO.) in 10 ml 0.5 M phosphate, at pH 7.6, 
and 60 ml horse serum (Difco Labs., West Molesey, 
Surrey) diluted with Hz0 to 100 ml. The charcoal 
was separated by centrifugation at 4°C for 15 min at 
3000 X g, the supernatant was removed by aspiration 
and the radioactive peptide assayed with the aid of 
a y-ray spectrometer. 
3. Results and discussion 
Porcine C-Fragment and human C-Fragment 
exhibited a high affinity for the antiserum (table 1). 
Porcine lipotropin (1-9 l), the COOH-terminal trideca- 
peptide of porcine lipotropin (79-91), and porcine 
C’-Fragment (61-87) displayed significant binding 
properties but the affinities were lower than that of 
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Table 1 
Cross reactivity of antiserum to fragments of 
porcine lipotropin 
Peptide Lipotropin Relative 
residue affinity 
(No.) (%I 
C-Fragment 61-91 100 
C-Fragment 61-87 9.8 
Tetradecapeptide 78-91 3.0 
y-Endorphin 61-77 <O.l 
Methionine enkephalin 61-65 <o. 1 
Lipotropin 1-91 71.4 
y-Lipotropin l-58 <O.l 
Peptides were tested in doses of less than 24 pmol. Anti- 
serum was used at a dilution of 1: 1000, with displacement 
of ‘251-labelled porcine C-Fragment. 
C-Fragment. Methionine enkephalin, y-endorphin and 
lipotropin did not bind to a significant extent (fig. 1). 
The results show that the antigenic site in C-Fragment 
must be located in the COOH-terminal region of the 
peptide and it appears that the COOH-terminal tetra- 
peptide represents a portion of the antigenic site since 
C’-Fragment was less potent than C-Fragment. That 
human C-Fragment exhibited binding properties 
equivalent to those of the porcine peptide indicates 
that the two replacements (isoleucine for valine at 
position 82 and tyrosine for histidine at position 87) 
are not involved in the interaction with antiserum, 
either directly or by influencing the disposition of 
neighbouring residues. 
When ‘251-labelled human or porcine C-Fragment 
was used with antiserum at a dilution of 1: 1000, it 
was possible to detect less than 0.02 pmol C-Fragment 
(as C-Fragment or lipotropin). When ‘251-labelled human 
lipotropin was used in place of the labelled C-Fragment, 
at an antiserum dilution of 1:22 000, there was no 
cross-reaction with human or porcine C-Fragment 
and less than 0.03 pmol human lipotropin could be 
detected. Thus this single antiserum provides a sen- 
sitive and specific assay for both human lipotropin 
and human C-Fragment. Clearly the lipotropin anti- 
body has a greater affinity for the NH,-terminal 
region of human lipotropin than for the COOH- 
terminal region and at low antibody concentration 
the NH*-terminus is the sole determinant. It is inter- 
esting to note that when labelled porcine lipotropin 
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Fig.1. Inhibition of binding of “’ I-labelled porcine C-Fragment to antiserum by lipotropin peptides. Antiserum was used at a 
dilution of 1:lOOO. Porcine C-Fragment (e-e), porcine lipotropin (o-o), C’-Fragment (A-A), lipotropin 78-91 (A-A), 
methionine enkephalin (v--v), y-endorphin (d-c) and y-lipotropin (m-m). 
was used, the NHz-terminal specificity was not 
observed. This can be attributed to the large number 
of differences in sequence which exist in the NH*- 
terminal region of human and porcine lipotropins. 
Evidence was obtained that C-Fragment or lipo- 
tropin is present in rat brain. When brain or cortex 
homogenates were examined by radioimmunoassay 
with [1251]C-Fragment, i  was found that the dis- 
placement curves were similar to that of authentic 
C-Fragment. Further study will reveal the concentra- 
tions of C-Fragment in tissue, plasma and cerebro- 
spinal fluid. 
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